Poly Medicure Ltd
Poly Medicure Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
The Company targets overall revenue growth of around 20% in the current year. Poly Medicure targets a revenue growth of around 20% overall for FY '26. - Domestic business expected to grow rapidly at 30%-32%, driven by Renal, Transfusion, and Vascular Access segments. - Renal business projected to grow approximately 50% in FY '26. - Export growth anticipated at 12%-15%, with Europe remaining a prime market. - EBITDA margins guided between 25%-27%, with potential upside if export growth exceeds 15%. - Operating margins in domestic business expected to improve in line with 30%-32% growth. - Renal business currently loss-making but expected to achieve operational leverage and margin improvements as scale builds. - Heavy CAPEX investment (~Rs.
From Poly Medicure Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The Company targets overall revenue growth of around 20% in the current year.
- Domestic business growth is expected to be robust, at approximately 30%-32%.
- Renal business is projected to grow significantly, with about 50%-60% growth anticipated for FY '26.
- Infusion (vascular access) domestic business is expected to grow at 18%-20% this year.
- Export revenue growth is forecast to be between 12%-15%, with Europe remaining a prime market.
- Renal market share in India is expected to rise from current 10%-12% to 15%-17% over the next 2-3 years.
- Installed base of dialysis machines aims to increase to 500-600 units sold annually, supporting growth in renal segment.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Poly Medicure Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Poly Medicure Limited is on a heavy CAPEX cycle with a planned investment of around Rs. 500 crores over the next 2 years.
- CAPEX is focused on building 3 new manufacturing facilities in Haryana, Uttarakhand, and Rajasthan.
- Two sites are already under construction, with the third expected to start soon, aiming for commercialization by end of Calendar Year 2026.
- Investments will primarily expand Renal capacity and explore new opportunities in the CDMO space leveraging new tariff structures.
- About Rs. 900 crores of recently raised QIP funds remain unutilized and will be partly used for CAPEX, working capital, and general corporate purposes.
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Poly Medicure Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Poly Medicure Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹535 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Poly Medicure Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q2 FY26 earnings call →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Healthcare Equipment & Supplies this season
- Vaidya Sane Ayurved Laboratories Ltd (Q4 FY25)
120 crores. Key concall takeaways from Vaidya Sane Ayurved Laboratories Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- OSEL Devices Ltd (Q4 FY25)
Current order-in-hand for OSEL Devices Limited is approximately INR 40-45 crores. Key concall takeaways from OSEL Devices Ltd's Q4 FY25 earnings call — and how…
- Prevest Denpro Ltd (Q4 FY25)
The management emphasizes growth in both domestic and export markets, indicating healthy order inflows aligned with a 13% sales increase in FY25. Key concall…
- Aprameya Enginee (Q4 FY25)
Current order book: Approximately INR 60 crores. Key concall takeaways from Aprameya Engineering Ltd's Q4 FY25 earnings call — and how it ranks against sector…
Frequently Asked Questions
What were Poly Medicure Ltd Q4 FY25 results?
The Company targets overall revenue growth of around 20% in the current year. Poly Medicure targets a revenue growth of around 20% overall for FY '26. - Domestic business expected to grow rapidly at 30%-32%, driven by Renal, Transfusion, and Vascular Access segments. - Renal business projected to grow approximately 50% in FY '26. - Export growth anticipated at 12%-15%, with Europe remaining a prime market. - EBITDA margins guided between 25%-27%, with potential upside if export growth exceeds 15%. - Operating margins in domestic business expected to improve in line with 30%-32% growth. - Renal business currently loss-making but expected to achieve operational leverage and margin improvements as scale builds. - Heavy CAPEX investment (~Rs.
What is Poly Medicure Ltd share price analysis?
Poly Medicure Ltd currently shows a neutral. The stock trades at a P/E of 52.9 with a market cap of ₹17,317 Cr. Investors should review the full earnings analysis for detailed insights.
Is Poly Medicure Ltd planning capital expenditure?
Poly Medicure Limited is on a heavy CAPEX cycle with a planned investment of around Rs.
Keep Poly Medicure Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.